The IT services firm strengthens its collaboration with Google Cloud to help enterprises move AI from pilot projects to production systems
Updated
February 18, 2026 8:11 PM
Google Cloud building. PHOTO: ADOBE STOCK
Enterprise interest in AI has moved quickly from experimentation to execution. Many organizations have tested generative tools, but turning those tools into systems that can run inside daily operations remains a separate challenge. Cognizant, an IT services firm, is expanding its partnership with Google Cloud to help enterprises move from AI pilots to fully deployed, production-ready systems.
Cognizant and Google Cloud are deepening their collaboration around Google’s Gemini Enterprise and Google Workspace. Cognizant is deploying these tools across its own workforce first, using them to support internal productivity and collaboration. The idea is simple: test and refine the systems internally, then package similar capabilities for clients.
The focus of the partnership is what Cognizant calls “agentic AI.” In practical terms, this refers to AI systems that can plan, act and complete tasks with limited human input. Instead of generating isolated outputs, these systems are designed to fit into business workflows and carry out structured tasks.
To make that workable at scale, Cognizant is building delivery infrastructure around the technology. The company is setting up a dedicated Gemini Enterprise Center of Excellence and formalizing an Agent Development Lifecycle. This framework covers the full process, from early design and blueprinting to validation and production rollout. The aim is to give enterprises a clearer path from the AI concept to a deployed system.
Cognizant also plans to introduce a bundled productivity offering that combines Gemini Enterprise with Google Workspace. The targeted use cases are operational rather than experimental. These include collaborative content creation, supplier communications and other workflow-heavy processes that can be standardized and automated.
Beyond productivity tools, Cognizant is integrating Gemini into its broader service platforms. Through Cognizant Ignition, enabled by Gemini, the company supports early-stage discovery and prototyping while helping clients strengthen their data foundations. Its Agent Foundry platform provides pre-configured and no-code capabilities for specific use cases such as AI-powered contact centers and intelligent order management. These tools are designed to reduce the amount of custom development required for each deployment.
Scaling is another element of the strategy. Cognizant, a multi-year Google Cloud Data Partner of the Year award winner, says it will rely on a global network of Gemini-trained specialists to deliver these systems. The company is also expanding work tied to Google Distributed Cloud and showcasing capabilities through its Google Experience Zones and Gen AI Studios.
For Google Cloud, the partnership reinforces its enterprise AI ecosystem. Cloud providers can offer models and infrastructure, but enterprise adoption often depends on service partners that can integrate tools into existing systems and manage ongoing operations. By aligning closely with Cognizant, Google strengthens its ability to move Gemini from platform capability to production deployment.
The announcement does not introduce a new AI model. Instead, it reflects a shift in emphasis. The core question is no longer whether AI tools exist, but how they are implemented, governed and scaled across large organizations. Cognizant’s expanded role suggests that execution frameworks, internal deployment and structured delivery models are becoming central to how enterprises approach AI.
In that sense, the partnership is less about new technology and more about operational maturity. It highlights how AI is moving from isolated pilots to managed systems embedded in business processes — a transition that will likely define the next phase of enterprise adoption.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.